Aura Biosciences, Inc. 8-K

What Happened
Aura Biosciences (AURA) announced that its board appointed Natalie Holles as Chief Executive Officer and President and as a Class I director, effective April 30, 2026. She succeeds founder and outgoing CEO Dr. Elisabet de los Pinos, who notified the company she is stepping down effective April 30, 2026 and will provide consulting services through October 30, 2026. The company furnished a press release on May 4, 2026 announcing the leadership change.

Key Details

• Effective date: Natalie Holles’ appointment and Dr. de los Pinos’ departure are effective April 30, 2026; Dr. de los Pinos will consult through October 30, 2026.
• Compensation for Holles: $700,000 annual base salary and a discretionary annual bonus target of 55% of base salary. She is eligible under the company’s Executive Severance Plan as a Tier One Executive.
• Equity inducement: Holles will receive an equity award equal to approximately 2.5% of the company’s outstanding common stock (about 75% as an option and 25% as RSUs) plus performance-based RSUs equal to ~0.5% of outstanding stock. Option exercise price = Nasdaq fair market value on grant date. Standard multi‑year vesting and performance conditions apply.
• Founder arrangements: Under a Consulting Agreement and Separation Agreement, Dr. de los Pinos gets accelerated vesting of outstanding equity through the consulting period (with full vesting if the company terminates without cause), extended exercise windows subject to a release, 12 months’ continued base salary as severance (subject to release), up to 18 months of health payment support (if she elects COBRA), and a prorated 2026 bonus.

Why It Matters
This is a material executive change: the company replaced its founder-CEO with an experienced industry executive who has rare-disease commercialization and corporate-development experience. The leadership change, the size and structure of Holles’ equity package (roughly 3% total potential equity awards), and the founder’s consulting and severance arrangements are important for investors because they affect management continuity, executive incentives, potential dilution, and near-term governance. The founder remains engaged as a consultant through October 2026, which may help with transition continuity. A press release was furnished with the 8-K (Exhibit 99.1).